COMPANY PROFILE

DelSiTech

DelSiTech has developed a unique proprietary technology making it a world leader in advanced biodegradable silica-based drug delivery

Turku, FinlandFounded 2001Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Revenue $10–50M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About DelSiTech

Delsitech specializes in advanced nanotechnology solutions for drug delivery, focusing on the controlled release of small molecules and biopharmaceuticals. The company operates in the pharmaceutical and biotechnology markets, targeting clients such as pharmaceutical companies, biotech firms, and healthcare providers. Delsitech's business model revolves around developing proprietary drug delivery systems and partnering with other companies to enhance their drug formulations. Revenue is generated through licensing agreements, partnerships, and the sale of proprietary drug products. The company aims to address high unmet clinical and commercial needs with innovative delivery technologies, ensuring products with high commercial potential.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2001
Headquarters: Turku, Finland
Employees: 56
Open positions: None listed
Dealroom signal: 64.1/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Health Care, Delivery, Biotechnology, Pharmaceutical, Hard Tech, DT and LS, science-based
Technology: Hardware, Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Jan 2024	$11M	$44M	DRW Venture Capital	↗
GRANTOther financing	Mar 2023	$0	—	Bill & Melinda Gates Foundation	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

DelSiTech website traffic

Latest recorded traffic for DelSiTech is 1.1K monthly website visits, up 0% over the last three months. DelSiTech's team declined 3.4% over the past year.

Latest monthly visits1.1K 3-month web change0% 1-year team growth-3.4%

Monthly website visitsNov 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CHChemifyDigitizing chemistry by developing technology to convert chemical code into molecules and vice versa	Glasgow, United Kingdom	Operational	196	$104M	$200M
MYMytosInfrastructure for fully automated manufacture of any human cell type	London, United Kingdom	Operational
RBReshape BiotechWorld's first AI and robotics powered imaging and analysis platform, researchers can finally automate visual assays and accelerate the pace of research	Kongens Lyngby, Denmark	Operational
CECeiboSecuring copper supplies for the energy transition requires innovative technologies and mining operations that minimize the impact on the environment and host communities	Santiago, Chile	Operational
EAElnora AIRewriting the rules of antiviral drug discovery	Tallinn, Estonia	Operational
BIBiomiaDevelops AI-designed, nature-inspired small-molecule drugs for central nervous system disorders using yeast-based biosynthetic production	Kongens Lyngby, Denmark	Operational
DCDUDE CHEMEnables greener outsourcing of active pharmaceutical ingredients and their intermediates in order to transform the current pharma-chemical industry towards an environmentally benign sector	Berlin, Germany	Operational
CACardiaTecApplying artificial intelligence on large-scale human multiomic data to develop the next generation of cardiovascular disease targets	Cambridge, United Kingdom	Operational